These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7272177)

  • 21. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.
    Korn A; Da Prada M; Raffesberg W; Gasic S; Eichler HG
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):17-23. PubMed ID: 2450251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
    Bieck PR; Antonin KH
    J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects.
    Patat A; Berlin I; Durrieu G; Armand P; Fitoussi S; Molinier P; Caille P
    J Clin Pharmacol; 1995 Jun; 35(6):633-43. PubMed ID: 7665725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
    Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H
    Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RS-2232, a compound with a reversible and specific type-A monoamine oxidase inhibiting property in mouse brain.
    Yokoyama T; Iwata N; Kobayashi T
    Jpn J Pharmacol; 1987 Aug; 44(4):421-7. PubMed ID: 3682407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.
    Gleiter CH; Mühlbauer B; Schulz RM; Nilsson E; Antonin KH; Bieck PR
    J Neural Transm Gen Sect; 1994; 95(3):241-5. PubMed ID: 7865179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.
    Blob LF; Sharoky M; Campbell BJ; Kemper EM; Gilmor MG; VanDenberg CM; Azzaro AJ
    CNS Spectr; 2007 Jan; 12(1):25-34. PubMed ID: 17192761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers.
    Berlin I; Zimmer R; Cournot A; Payan C; Pedarriosse AM; Puech AJ
    Clin Pharmacol Ther; 1989 Sep; 46(3):344-51. PubMed ID: 2673623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoamine oxidase B inhibition and the "cheese effect".
    Youdim MB; Finberg JP
    J Neural Transm Suppl; 1987; 25():27-33. PubMed ID: 3480939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase.
    Dollery CT; Brown MJ; Davies DS; Lewis PJ; Strolin-Benedetti M
    Clin Pharmacol Ther; 1983 Nov; 34(5):651-62. PubMed ID: 6627826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology of reversible monoamine oxidase-A inhibitors.
    Bieck PR; Antonin KH; Schmidt E
    Clin Neuropharmacol; 1993; 16 Suppl 2():S34-41. PubMed ID: 8313395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of moclobemide.
    Haefely W; Burkard WP; Cesura A; Colzi A; Kettler R; Lorez HP; Martin JR; Moreau JL; Richards JG; Schaffner R
    Clin Neuropharmacol; 1993; 16 Suppl 2():S8-18. PubMed ID: 8313402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
    Dingemanse J; Hussain Y; Korn A
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M; Keller HH; Kettler R
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on the mechanism of action of caroxazone, a new antidepressant drug.
    Moretti A; Caccia C; Calderini G; Menozzi M; Amico A
    Biochem Pharmacol; 1981 Oct; 30(19):2728-31. PubMed ID: 6170295
    [No Abstract]   [Full Text] [Related]  

  • 36. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin.
    Kato M; Katayama T; Iwata H; Yamamura M; Matsuoka Y; Narita H
    J Pharmacol Exp Ther; 1998 Mar; 284(3):983-90. PubMed ID: 9495858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor.
    Rovei V; Caille D; Curet O; Ego D; Jarreau FX
    J Neural Transm Suppl; 1994; 41():339-47. PubMed ID: 7931248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-clinical pharmacology of moclobemide. A review of published studies.
    Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
    Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiation of the pressor effect of intravenously administered tyramine during moclobemide treatment.
    Zimmer R; Fischbach R; Breuel HP
    Acta Psychiatr Scand Suppl; 1990; 360():76-7. PubMed ID: 2248082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.